ReviewHIV medicine2016
HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
Review in HIV medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Integrating hypertension screening at the time of voluntary HIV testing among adults in South Africa.PloS one · 2019Trial
- Connection Between HIV and Mitochondria in Cardiovascular Disease and Implications for Treatments.Circulation research · 2024Review
- Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.Clinical pharmacology and therapeutics · 2023Review
- VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy.Viruses · 2022Article
- Linear and non-linear analysis of heart rate variability in HIV-positive patients on two different antiretroviral therapy regimens.BMC infectious diseases · 2021Article
- Article
- Review
- Premature Atherosclerotic Cardiovascular Disease: What Have We Learned Recently?Current atherosclerosis reports · 2020Review
- Plasma microRNA expression levels in HIV-1-positive patients receiving antiretroviral therapy.Bioscience reports · 2020Article
- Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study.Drug design, development and therapy · 2019Observational
- The systematic development of a complex intervention: HealthMap, an online self-management support program for people with HIV.BMC infectious diseases · 2018Article
- Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression.Journal of leukocyte biology · 2018Article
- Insulin Resistance in HIV-Patients: Causes and Consequences.Frontiers in endocrinology · 2018Review
- HIV-Associated Cardiovascular Disease: Role of Connexin 43.The American journal of pathology · 2017Article
- Isolated pons involvement in Posterior Reversible Encephalopathy Syndrome: Case report and review of the literature.eNeurologicalSci · 2017Review
- Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.Toxicologic pathology · 2016Article
- Complications of Treatment in Youth with HIV.Current HIV/AIDS reports · 2016Review
- Ecological Study of HIV Infection and Hypertension in Sub-Saharan Africa: Is There a Double Burden of Disease?PloS one · 2016Article
- Solving the Blood-Brain Barrier Challenge for the Effective Treatment of HIV Replication in the Central Nervous System.Current pharmaceutical design · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a "new" chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors such as smoking, hypertension, insulin resistance and dyslipidaemia, infection with HIV is an independent risk factor for CVD. This review summarizes: (1) the vascular and nonvascular cardiac manifestations of HIV infection; (2) cardiometabolic effects of HAART; (3) atherosclerotic cardiovascular disease (ASCVD) risk assessment, prevention and treatment in persons with HIV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.